These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 15953364)

  • 1. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease.
    Lafay-Chebassier C; Paccalin M; Page G; Barc-Pain S; Perault-Pochat MC; Gil R; Pradier L; Hugon J
    J Neurochem; 2005 Jul; 94(1):215-25. PubMed ID: 15953364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer's disease.
    Damjanac M; Rioux Bilan A; Paccalin M; Pontcharraud R; Fauconneau B; Hugon J; Page G
    Neurobiol Dis; 2008 Feb; 29(2):354-67. PubMed ID: 18023354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunosuppressant rapamycin exacerbates neurotoxicity of Abeta peptide.
    Lafay-Chebassier C; Pérault-Pochat MC; Page G; Rioux Bilan A; Damjanac M; Pain S; Houeto JL; Gil R; Hugon J
    J Neurosci Res; 2006 Nov; 84(6):1323-34. PubMed ID: 16955484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
    Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
    Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes.
    Kurt MA; Davies DC; Kidd M; Duff K; Rolph SC; Jennings KH; Howlett DR
    Exp Neurol; 2001 Sep; 171(1):59-71. PubMed ID: 11520121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.
    Pihlaja R; Koistinaho J; Malm T; Sikkilä H; Vainio S; Koistinaho M
    Glia; 2008 Jan; 56(2):154-63. PubMed ID: 18004725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.
    Mohmmad Abdul H; Sultana R; Keller JN; St Clair DK; Markesbery WR; Butterfield DA
    J Neurochem; 2006 Mar; 96(5):1322-35. PubMed ID: 16478525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer's disease.
    Page G; Rioux Bilan A; Ingrand S; Lafay-Chebassier C; Pain S; Perault Pochat MC; Bouras C; Bayer T; Hugon J
    Neuroscience; 2006; 139(4):1343-54. PubMed ID: 16581193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice.
    Hartmann J; Erb C; Ebert U; Baumann KH; Popp A; König G; Klein J
    Neuroscience; 2004; 125(4):1009-17. PubMed ID: 15120860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced accumulation of tau in doubly transgenic mice expressing mutant betaAPP and presenilin-1.
    Samura E; Shoji M; Kawarabayashi T; Sasaki A; Matsubara E; Murakami T; Wuhua X; Tamura S; Ikeda M; Ishiguro K; Saido TC; Westaway D; St George Hyslop P; Harigaya Y; Abe K
    Brain Res; 2006 Jun; 1094(1):192-9. PubMed ID: 16713590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition.
    Flood DG; Lin YG; Lang DM; Trusko SP; Hirsch JD; Savage MJ; Scott RW; Howland DS
    Neurobiol Aging; 2009 Jul; 30(7):1078-90. PubMed ID: 18053619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
    Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
    Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP.
    Li L; Zhang X; Yang D; Luo G; Chen S; Le W
    Neurobiol Aging; 2009 Jul; 30(7):1091-8. PubMed ID: 18063223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].
    Xu BG; Wu X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):201-9. PubMed ID: 15171563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease.
    El Tannir El Tayara N; Delatour B; Le Cudennec C; Guégan M; Volk A; Dhenain M
    Neurobiol Dis; 2006 Apr; 22(1):199-208. PubMed ID: 16337798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
    Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
    Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.